Showing results (131-140 of 160) with videos related to
Sort By:
Pageof 16
Lung Cancer (Auckland, N.Z.)|June 28, 2024
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus SurveySai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2025
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN StudyYi-Long Wu, Hye Ryun Kim, Ross A Soo, et al.EMBO Molecular Medicine|October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancerMi Ran Yun, Hun Mi Choi, You Won Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancerSuresh S Ramalingam, Mikhail Shtivelband, Ross A Soo, et al.Cancers|October 28, 2023
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)Yvonne L E Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, et al.JTO Clinical and Research Reports|May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLCQing Zhou, Ross A Soo, Gee-Chen Chang, et al.The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.European Journal of Cancer (Oxford, England : 1990)|July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancerEnriqueta Felip, Giulio Metro, Ross A Soo, et al.Frontiers in Oncology|May 30, 2024
Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unitRobert John Walsh, Rebecca Ong, Seng Wee Cheo, et al.The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.Pageof 16